Pharmacokinetic evaluation of the effects of ribavirin on zidovudine triphosphate formation: ACTG 5092s study team

HIV Medicine

Volumn 8, Issue 5, 2007, Pages 288-294

  Aweeka, F T ^a   Kang, M ^b   Yu, J Y ^c   Lizak, P ^a   Alston, B ^d   Chung, R T ^e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c FRONTIER SCIENCE AND TECHNOLOGY RESEARCH FOUNDATION   (United States)

^d Division of AIDS   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Hepatitis C virus treatment; Intracellular zidovudine; Pharmacokinetics; Ribavirin

Indexed keywords

ANTIRETROVIRUS AGENT; RIBAVIRIN; ZIDOVUDINE 5' TRIPHOSPHATE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD LEVEL; CELL LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DETERMINATION; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIQUID CHROMATOGRAPHY; MULTICENTER STUDY; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; STATISTICAL SIGNIFICANCE; STEADY STATE; TANDEM MASS SPECTROMETRY; TREND STUDY;

ADULT; ANTIVIRAL AGENTS; AREA UNDER CURVE; DRUG INTERACTIONS; HEPACIVIRUS; HEPATITIS C, CHRONIC; HIV INFECTIONS; HIV-1; HUMANS; MIDDLE AGED; PHOSPHORYLATION; REVERSE TRANSCRIPTASE INHIBITORS; RIBAVIRIN; ZIDOVUDINE;

EID: 34250182706     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2007.00472.x     Document Type: Article

References (13)

1. Furman PA, Fyfe JA, St Clair MH et al. Phopshorylation of 3′-azido-3′-deoxythymidine and selective interaction of the 5′-triphosphate with human inmmunodeficiency virus reverse transcriptase. Proc Natl Acad Sci USA 1986; 83: 8333-8337.
2. Mitsuya H, Yarchoan R, Broder S. Molecular targets for AIDS therapy. Science 1990; 249: 1533-1544.
3. Balzarini J, Lee CK, Herdewijn, De Clercq E. Mechanism of the potentiating effect of ribavirin on the activity of 2′,3′-dideoxyinosine against human immunodeficiency virus. J Biol Chem 1991; 266: 21509-21514.
4. Hoggard PG, Kewn S, Barry MG, Khoo SH, Back DJ. Effects of drugs on 2′,3′-dideoxy-2′,3′-didehydrothymidine phosphorylation in vitro. Antimicrob Agents Chemother 1997; 41: 1231-1236.
5. Vogt MW, Hartshorn KL, Furman PA. Ribavirin antagonizes the effect of azidothymidine on HIV replication. Science 1987; 235: 1376-1379.
6. Baba M, Pauwels R, Balzarini J, Herdewijn P, De Clercq E, Desmyter J. Ribavirin antagonizes inhibitory effects of pyrimidine 2′,3′-dideoxynucleosides but enhances inhibitory effects of purine 2′,3′-dideoxynucleosides on replication of human immunodeficiency virus in vitro. Antimicrob Agents Chemother 1987; 31: 1613-1617.
7. Chung RT, Anderson J, Volberding P et al. Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV co-infected patients. N Eng J Med 2004; 351: 451-459.
8. Thevanayagam LN, Jayewardene AL, Gambertoglio JG. The stability of intracellular zidovudine and its anabolites in extracts of peripheral blood mononuclear cells (PBMCs). J Pharm Biomed Anal 2000; 22: 597-603.
9. Rodriguez-Torres M, Torriani FJ, Soriano V et al. Effect of ribavirin on intracellular and plasma pharmacokinetics of nucleoside reverse transcriptase inhibitors in patients with human immunodeficiency virus-hepatitis C virus coinfection: Results of a randomized clinical study. Antimicrob Agents Chemother 2005; 49: 3997-4008.
10. Rendon AL, Nunez M, Romero M et al. Early monitoring of ribavirin plasma concentrations may predict anemia and early virologic response in HIV/ hepatitis C virus-coinfected patients. J Acquir Immune Defic Syndr 2005; 39: 401-405.
11. Tod M, Farcy-Afif M, Stocco J et al. Pharmacokinetic/pharmacodynamic and time to event models of ribavirin-induced anemia in chronic hepatitis C. Clin Pharmacokin 2005; 44: 417-428.
12. Lertora JJ, Rege AB, Lacour JT et al. Pharmacokinetics and long-term tolerance to ribavirin in asymptomatic patients infected with human immunodeficiency virus. Clin Pharmacol Ther 1991; 50: 442-449.
13. Swindells S, Cohen CJ, Berger DS et al. Abacavir, efavirenz, didanosine with or without hydroxyurea in HIV infected adults failing initial nucleoside/protease inhibitor-containing regimens. BMC Infect Dis 2005; 5: 23.